Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes
Vissia Viglietta, … , Tihamer Orban, David A. Hafler
Vissia Viglietta, … , Tihamer Orban, David A. Hafler
Published April 1, 2002
Citation Information: J Clin Invest. 2002;109(7):895-903. https://doi.org/10.1172/JCI14114.
View: Text | PDF | Corrigendum
Article Immunology

GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes

  • Text
  • PDF
Abstract

Insulin-dependent type 1 diabetes is an autoimmune disease mediated by T lymphocytes recognizing pancreatic islet cell antigens. Glutamic acid decarboxylase 65 (GAD65) appears to be an important autoantigen in the disease. However, T cells from both patients with type 1 diabetes and healthy subjects vigorously proliferate in response to GAD65 stimulation ex vivo, leading us to postulate that the critical event in the onset of human diabetes is the activation of autoreactive T cells. Thus, we investigated whether GAD65-reactive T cells in patients with diabetes functioned as previously activated memory T cells, no longer requiring a second, costimulatory signal for clonal expansion. We found that in patients with new-onset type 1 diabetes, GAD65-reactive T cells were strikingly less dependent on CD28 and B7-1 costimulation to enter into cell cycle and proliferate than were equivalent cells derived from healthy controls. We hypothesize that these autoreactive T cells have been activated in vivo and have differentiated into memory cells, suggesting a pathogenic role in type 1 diabetes. In addition, we observed different effects with selective blockade of either B7-1 or B7-2 molecules; B7-1 appears to deliver a negative signal by engaging CTLA-4, while B7-2 engagement of CD28 upregulates T cell proliferation and cytokine secretion.

Authors

Vissia Viglietta, Sally C. Kent, Tihamer Orban, David A. Hafler

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Differential effects of anti–B7-1 and anti–B7-2. PBMCs were cultured wit...
Differential effects of anti–B7-1 and anti–B7-2. PBMCs were cultured with different concentration of GAD65 in the presence or absence of anti–B7-1 F(ab′) or anti–B7-2 F(ab′) mAb’s. Anti–B7-1 F(ab′) fragments inhibited the proliferative and cytokine response to GAD65 at all antigen concentrations in healthy subjects (filled circles), similar to anti-CD28, but only at low antigen concentration in patients with type 1 diabetes (open circles). The difference between the two groups was significant (patients vs. controls, proliferation: GAD 10 μg/ml, P = 0.0079; GAD 20 μg/ml, P = 0.001; IFN-γ: GAD 10 μg/ml, P = 0.01; GAD 20 μg/ml, P = 0.001; IL-13: GAD 10 μg/ml, P = 0.01; GAD 20 μg/ml, P = 0.001). In contrast anti–B7-2 decreased the proliferative and cytokine response in both normal controls and diabetic patients.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts